newsfilter
← Earnings
Earnings Releases·

Tenaya Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue reached $1.7 million in Q3 2026 compared to $0 in the prior year period, while net loss narrowed to $18.9 million ($0.08/share) from $20.3 million ($0.12/share) in Q3 2025.
  • Cash and cash equivalents decreased to $66.8 million as of September 30, 2026, from $100.5 million at year-end 2025, though current resources are projected to fund operations through Q4 2027.
  • TN-401 received FDA RMAT designation in September 2026 following positive interim data, while TN-201 and TN-401 are scheduled to report longer-term clinical data and regulatory feedback updates by year-end.
  • The company plans to initiate at least one Phase 2 trial for TN-301 in the second half of 2027, with management indicating that upcoming data will guide future capital allocation.
Company
TENAYA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology